This study is a prospective, open-label extension of the placebo-controlled MADAI trial, including 22 patients with stable relapsing-remitting multiple sclerosis. Participants received oral PA (500 mg twice daily) for an additional 9 months follow-up (FU). Multimodal assessments included safety and tolerability, cognitive testing (SDMT), physical performance (9HPT, 10mWT), and patient-reported outcome measurements PROMs (SF-36, FSMC, ESS, BDI-II).
